Skip to content
★ Sign in to follow
MG

Michael Geffner

Executive
Chief Medical Officer
Insider activity · 24 months0 buys7 salesCumulative net flow
Total declarations
13
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (11 ops.)
€890k

Latest filing published 24 Oct 2025 for Immunovant, Inc., €43k.

Filing timeline

BuySale
Michael Geffner

Insider track record

Disclosed buys
0
Disclosed sells
11
Signal history

Michael Geffner: trading record in brief

This profile gathers the share dealings of Michael Geffner in Immunovant, Inc., where the filings describe the role as senior executive. The record holds 13 filings, for trades running from 26 January 2024 to 22 October 2025.

The open-market record consists of 11 sales worth €890k, with no purchase. Outside the open market, there are 2 share grants. In 2025 alone, the filings show no purchases and 7 sales.

The newest entry dates from 24 October 2025: an open-market sale of €43k, in Immunovant, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Michael Geffner

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations13 total
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    49,383 USD23SEC
    2,595 shares@ US$19.030.0005% mcap4.8% of flowCommon StockSEC:0001764013-25-000144:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    20,734 USD23SEC
    1,272 shares@ US$16.300.0002% mcap2.0% of flowCommon StockSEC:0001764013-25-000140:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    43,288 USD23SEC
    2,385 shares@ US$18.154.1% of flowCommon StockSEC:0001764013-25-000114:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    19,998 USD23SEC
    1,160 shares@ US$17.240.0002% mcap1.9% of flowCommon StockSEC:0001764013-25-000109:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    34,742 USD29SEC
    2,349 shares@ US$14.793.4% of flowCommon StockSEC:0001764013-25-000082:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    80,135 USD30SEC
    6,169 shares@ US$12.998.2% of flowCommon StockSEC:0001764013-25-000068:0
  • ◆
    Chief Medical OfficerExecutivesImmunovant, Inc.
    0SEC
    101,574 shares0Common StockSEC:0001764013-25-000053:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    62,679 USD30SEC
    2,657 shares@ US$23.596.8% of flowCommon StockSEC:0001764013-25-000018:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    94,171 USD30SEC
    3,189 shares@ US$29.539.8% of flowCommon StockSEC:0001764013-24-000179:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    95,939 USD30SEC
    3,456 shares@ US$27.769.9% of flowCommon StockSEC:0001764013-24-000142:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    94,243 USD30SEC
    3,261 shares@ US$28.909.9% of flowCommon StockSEC:0001764013-24-000089:0
  • ◆
    Chief Medical OfficerExecutivesImmunovant, Inc.
    0SEC
    54,978 shares0Common StockSEC:0001764013-24-000050:0
  • ▼
    Chief Medical OfficerExecutivesImmunovant, Inc.
    377,129 USD33SEC
    9,948 shares@ US$37.9139.1% of flowCommon StockSEC:0001764013-24-000017:0

13 of 13 declarations